期刊
MOLECULAR THERAPY
卷 28, 期 3, 页码 709-722出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2020.01.001
关键词
-
资金
- National Institutes of Health/National Institute of Allergy and Infectious Diseases Grant [R01 AI51390]
- National Institutes of Health/National Heart, Lung, and Blood Institute [R01 HL131093, R01 HL097088]
- Indiana Collaborative Initiative for Talent Enrichment (INCITE) funds by the Lilly Endowment
Several viral vector-based gene therapy drugs have now received marketing approval. A much larger number of additional viral vectors are in various stages of clinical trials for the treatment of genetic and acquired diseases, with many more in pre-clinical testing. Efficiency of gene transfer and ability to provide long-term therapy make these vector systems very attractive. In fact, viral vector gene therapy has been able to treat or even cure diseases for which there had been no or only suboptimal treatments. However, innate and adaptive immune responses to these vectors and their transgene products constitute substantial hurdles to clinical development and wider use in patients. This review provides an overview of the type of immune responses that have been documented in animal models and in humans who received gene transfer with one of three widely tested vector systems, namely adenoviral, lentiviral, or adeno-associated viral vectors. Particular emphasis is given to mechanisms leading to immune responses, efforts to reduce vector immunogenicity, and potential solutions to the problems. At the same time, we point out gaps in our knowledge that should to be filled and problems that need to be addressed going forward.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据